BacMam-Enabled LanthaScreen®cellular assays for PI3K/Akt pathway compound profiling in disease-Relevant cell backgrounds

Journal of Biomolecular Screening

Volumn 15, Issue 3, 2010, Pages 327-334

  Carlson, Coby B ^a   Mashock, Michael J ^a   Kun, B I ^a  

^a INVITROGEN CORPORATION   (United States)

Author keywords

Baculovirus; Cell based assays; GFP; HTS; PI3K

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (1H INDAZOL 4 YL) 6 (4 METHANESULFONYL 1 PIPERAZINYLMETHYL) 4 MORPHOLINOTHIENO[3,2 D]PYRIMIDINE; 2 (2 DIFLUOROMETHYLBENZIMIDAZOL 1 YL) 4,6 DIMORPHOLINO 1,3,5 TRIAZINE; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; 5 (6 QUINOXALINYLMETHYLENE) 2,4 THIAZOLIDINEDIONE; 9 (1 ANILINOETHYL) 7 METHYL 2 MORPHOLINOPYRIDO[1,2 A]PYRIMIDIN 4 ONE; A 443654; ADENOSINE TRIPHOSPHATE; BENZIMIDAZOLE DERIVATIVE; COMPOUND 5233705; GREEN FLUORESCENT PROTEIN; HYBRID PROTEIN; INDAZOLE DERIVATIVE; KP372 1; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PIK 75; PIK 90; PK 866; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PURINE DERIVATIVE; PYRIDINE DERIVATIVE; QUINOXALINE DERIVATIVE; TG100 115; TRICIRIBINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; BACULOVIRUS; CANCER CELL CULTURE; CELL ASSAY; CELL TYPE; DOSE RESPONSE; DRUG RESEARCH; DRUG TARGETING; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE DELIVERY SYSTEM; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; MAMMAL CELL; NONHUMAN; PLASMID; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TECHNOLOGY; VIRAL GENE DELIVERY SYSTEM;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BIOLOGICAL ASSAY; CELL LINE, TUMOR; GREEN FLUORESCENT PROTEINS; HUMANS; INHIBITORY CONCENTRATION 50; MUTATION; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION;

EID: 77949390747     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057109357788     Document Type: Article

References (19)

1. Garcia-Echeverria C, Sellers WR: Drug discovery approaches targeting the PIK3/Akt pathway in cancer. Oncogene 2008; 27: 5511-5526.
2. Hennessy BT, Smith DL, Ram PT, Lu L, Mills GB: Exploiting the PI3K/ AKT pathway for cancer drug discoveiy. Nat Rev 2005; 4: 988-1004.
3. Carlson CB, Robers MB, Vogel KW, Machleidt T: Development of LanthaScreen cellular assays for key components within the PI3K/AKT/ mTOR pathway. J Biomol Screen 2009; 14: 121-133.
4. Huwiler KG, Machleidt T, Chase L, Hanson B, Robers MB: Characterization of serotonin 5-hydroxytryptamine-1A receptor activation using a phospho-extracellular-signal regulated kinase 2 sensor. Anal Biochem 2009; 393: 95-104.
5. Robers MB, Horton RA, Bercher MR, Vogel KW, Machleidt T: Highthroughput cellular assays for regulated post-translational modifications. Anal Biochem 2008; 372: 189-197.
6. Robers MB, Machleidt T, Carlson CB, Bi K: Cellular LanthaScreen and beta-lactamase reporter assays for high-throughput screening of JAK2 inhibitors. ASSAY Drug Dev Technol 2008; 6: 519-529.
7. Kost TA, Condreay JP, Ames RS, Rees S, Romanos MA: Implementation of BacMam virus gene delivery technology in a drug discovery setting. Drug Discov Today 2007; 12: 396-403.
8. Nascimento EB, Ouwens DM: PR.AS40: target or modulator of mTORCl signalling and insulin action? Arch Physiol Biochem 2009; 115: 1-13.
9. Ames RS, Kost TA, Condreay JP: BacMam technology and its application to drug discovery. Expert Opin Drug Discov 2007; 2: 1669-1681.
10. Condreay JP, Witherspoon SM, Clay WC, Kost TA: Transient and stable gene expression in mammalian cells transduced with a recombinant baculovirus vector. Proc Natl Acad Sci USA 1999; 96: 127-132.
11. Chaussade C, Rewcastle GW, Kendall JD, Denny WA, Clio K, Grønning LM, et al: Evidence for functional redundancy of class IA PI3K isoforms in insulin signaling. Biochem J 2007; 404: 449-458.
12. Torbett NE, Luna A, Knight ZA, Houk A, Moasser M, Weiss W, et al: A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isotype-selective inhibition. Biochem J 2008; 415: 97-110.
13. Camps M, Ruckle T, Ji H, Ardissone V, Rintelen F, Shaw J, et al: Blockade of PI3Ky suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med 2005; 11: 936-943.
14. Crowell JA, Steele VE, Fay JR: Targeting the AKT protein kinase for cancer chemoprevention. Mol Cancer Ther 2007; 6: 2139-2148.
15. Granville CA, Memmott RM, Gills JJ, Dennis PA: Handicapping the race to develop inhibitors of the pliosphoinositide-3-kinase/Akt/mammalian target of rapamycin pathway. Clin Cancer Res 2006; 12: 679-689.
16. Nakatani K, Thompson DA, Barthel A, Sakaue H, Liu W, Weigel RJ, et al: Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem 1999; 274: 21528-21532.
17. She Q-B, Chandarlapaty S, Ye Q, Lobo J, Haskell KM, Leander KR, et al: Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS ONE 2008; 3: e3065.
18. Mandai M, Kim S, Younes MN, Jasser SA, E1-Naggar AK, Mills GB, et al: The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells. Br J Cancer 2005; 92: 1899-1905.
19. Luo Y, Shoemaker AR, Liu X, Woods KW, Thomas SA, de Jong R, et al: Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol Cancer Ther 2005; 4: 977-986.